kabutan

Nxera Pharma Co., Ltd.(4565) Summary

4565
TSE Prime
Nxera Pharma Co., Ltd.
864
JPY
+9
(+1.05%)
Dec 12, 3:30 pm JST
5.54
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
859.5
Dec 12, 10:05 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.19
Yield
ー%
Margin Trading Ratio
456.65
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
863 JPY 5.54 USD
Previous Close Dec 11
855 JPY 5.47 USD
High Dec 12, 9:02 am
875 JPY 5.62 USD
Low Dec 12, 1:16 pm
851 JPY 5.46 USD
Volume
510,000
Trading Value
0.44B JPY 2.82M USD
VWAP
861.83 JPY 5.53 USD
Minimum Trading Value
86,400 JPY 554 USD
Market Cap
0.08T JPY 0.50B USD
Number of Trades
745
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
1,280
1-Year High Jun 2, 2025
4,353
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 177,300 5,498,100 31.01
Nov 28, 2025 185,300 5,274,200 28.46
Nov 21, 2025 174,200 4,942,800 28.37
Nov 14, 2025 154,700 4,895,200 31.64
Nov 7, 2025 155,400 5,010,600 32.24
Company Profile
Nxera Pharma Co., Ltd. is a drug discovery venture specializing in the development of drugs targeting membrane protein GPCRs in areas such as neurology, immunology, and gastroenterology.
Sector
Pharmaceuticals
Nxera Pharma Co., Ltd. is a biopharmaceutical company with a core focus on a drug discovery platform targeting GPCRs (G protein-coupled receptors), handling everything from research and development to sales of pharmaceuticals. The company is actively pursuing a growth strategy through acquisitions. Its UK subsidiary is responsible for drug discovery, translational medicine, preclinical and early clinical development. Clinical development and sales in Japan and Korea are managed by a wholly-owned subsidiary based in Japan and a subsidiary based in Korea, respectively. The company also envisions future business expansion into the APAC (Asia-Pacific) region. Nxera Pharma's strengths lie in GPCR structural analysis using StaR technology, early-stage lead compound generation, and candidate exploration. The company has established a global drug discovery network.